scholarly journals Dramatic polarization in genitourinary expert opinions regarding the clinical utility of positron emission tomography (PET) imaging in prostate cancer

2019 ◽  
Vol 45 (1) ◽  
pp. 23-31 ◽  
Author(s):  
Kiri A. Sandler ◽  
Shearwood McClelland III ◽  
Catherine Degnin ◽  
Yiyi Chen ◽  
Timur Mitin
Keyword(s):  
Prostate Cancer ◽  
Positron Emission Tomography ◽  
Pet Imaging ◽  
Clinical Utility ◽  
Emission Tomography ◽  
Expert Opinions ◽  
Positron Emission

scholarly journals A Review of Diagnostic Impact of Amyloid Positron Emission Tomography Imaging in Clinical Practice

2018 ◽  
Vol 46 (3-4) ◽  
pp. 154-167 ◽  
Author(s):  
Yejin Kim ◽  
Paul Rosenberg ◽  
Esther Oh
Keyword(s):  
Positron Emission Tomography ◽  
Clinical Practice ◽  
Pet Imaging ◽  
Clinical Utility ◽  
Patient Management ◽  
Emission Tomography ◽  
Amyloid Pet ◽  
Diagnostic Confidence ◽  
Positron Emission ◽  
Amyloid Pet Imaging

Background: Molecular imaging of brain amyloid for the diagnosis of Alzheimer’s disease (AD) using positron emission tomography (PET) has been approved for use in clinical practice by the Food and Drug Administration (FDA) since 2012. However, the clinical utility and diagnostic impact of amyloid PET imaging remain controversial. We conducted a review of the recent studies investigating clinical utility of amyloid PET imaging with focus on changes in diagnosis, diagnostic confidence, and patient management. Summary: A total of 16 studies were included in the final analysis. Overall rate of changes in diagnosis after amyloid PET ranged from 9 to 68% (pooled estimate of 31%, 95% CI 23–39%). All studies reported overall increase in diagnostic confidence or diagnostic certainty after amyloid PET. Changes in patient management ranged from 37 to 87%; the most common type of change in management reported was either the initiation or discontinuation of planned AD medications. Key Messages: Amyloid PET imaging led to moderate to significant changes in diagnosis, diagnostic confidence, and subsequent patient management. It may be most useful in patients with high level of diagnostic uncertainty even after the completing the standard workup.

Clinical utility of18F-fluorocholine positron-emission tomography/computed tomography (PET/CT) in biochemical relapse of prostate cancer after radical treatment: results of a multicentre study

2015 ◽  
Vol 115 (6) ◽  
pp. 874-883 ◽  
Author(s):  
Sonia Rodado-Marina ◽  
Mónica Coronado-Poggio ◽  
Ana María García-Vicente ◽  
Jose Ramón García-Garzón ◽  
Juan Carlos Alonso-Farto ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Computed Tomography ◽  
Positron Emission Tomography ◽  
Multicentre Study ◽  
Clinical Utility ◽  
Emission Tomography ◽  
Biochemical Relapse ◽  
Treatment Results ◽  
Positron Emission ◽  
Pet Ct

scholarly journals Positron Emission Tomography (PET) Imaging of Prostate Cancer with a Gastrin Releasing Peptide Receptor Antagonist - from Mice to Men

Theranostics ◽  
2014 ◽  
Vol 4 (4) ◽  
pp. 412-419 ◽  
Author(s):  
Gesche Wieser ◽  
Rosalba Mansi ◽  
Anca L. Grosu ◽  
Wolfgang Schultze-Seemann ◽  
Rebecca A. Dumont-Walter ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Positron Emission Tomography ◽  
Receptor Antagonist ◽  
Pet Imaging ◽  
Emission Tomography ◽  
Peptide Receptor ◽  
Gastrin Releasing Peptide ◽  
Positron Emission

679 A PILOT STUDY OF ZR89-J591 POSITRON EMISSION TOMOGRAPHY (PET) IMAGING IN MEN WITH PROSTATE CANCER UNDERGOING RADICAL PROSTATECTOMY

2013 ◽  
Vol 189 (4S) ◽  
Author(s):  
David Green ◽  
Shoaib B. Fareedy ◽  
Joseph R. Osborne ◽  
Brian D. Robinson ◽  
Sagit Goldenberg ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Positron Emission Tomography ◽  
Pilot Study ◽  
Radical Prostatectomy ◽  
Pet Imaging ◽  
Emission Tomography ◽  
Positron Emission

scholarly journals [68Ga]Ga-PSMA-11: The First FDA-Approved 68Ga-Radiopharmaceutical for PET Imaging of Prostate Cancer

2021 ◽  
Vol 14 (8) ◽  
pp. 713
Author(s):  
Ute Hennrich ◽  
Matthias Eder
Keyword(s):  
Prostate Cancer ◽  
United States ◽  
Positron Emission Tomography ◽  
Pet Imaging ◽  
The United States ◽  
Emission Tomography ◽  
Prostate Specific Membrane Antigen ◽  
Therapy Planning ◽  
Positron Emission ◽  
Specific Membrane

For the positron emission tomography (PET) imaging of prostate cancer, radiotracers targeting the prostate-specific membrane antigen (PSMA) are nowadays used in clinical practice. Almost 10 years after its discovery, [68Ga]Ga-PSMA-11 has been approved in the United States by the Food and Drug Administration (FDA) as the first 68Ga-radiopharmaceutical for the PET imaging of PSMA-positive prostate cancer in 2020. This radiopharmaceutical combines the peptidomimetic Glu-NH-CO-NH-Lys(Ahx)-HBED-CC with the radionuclide 68Ga, enabling specific imaging of tumor cells expressing PSMA. Such a targeting approach may also be used for therapy planning as well as potentially for the evaluation of treatment response.

scholarly journals Diagnostic Performance of PET Imaging Using Different Radiopharmaceuticals in Prostate Cancer According to Published Meta-Analyses

Cancers ◽  
2020 ◽  
Vol 12 (8) ◽  
pp. 2153 ◽  
Author(s):  
Salvatore Annunziata ◽  
Daniele Antonio Pizzuto ◽  
Giorgio Treglia
Keyword(s):  
Prostate Cancer ◽  
Positron Emission Tomography ◽  
Pet Imaging ◽  
Diagnostic Performance ◽  
Emission Tomography ◽  
Cochrane Library ◽  
Evidence Based ◽  
Positron Emission ◽  
Pet Ct ◽  
Meta Analyses

A significant number of meta-analyses reporting data on the diagnostic performance of positron emission tomography (PET) in prostate cancer (PCa) is currently available in the literature. In particular, different PET radiopharmaceuticals were used for this purpose. The aim of this review is to summarize information retrieved by published meta-analyses on this topic. The first step included a systematic search of the literature (last search date: June 2020), screening two databases (PubMed/MEDLINE and Cochrane Library). This combination of key words was used: (A) “PET” OR “positron emission tomography” AND (B) “prostate” OR “prostatic” AND (C) meta-analysis. Only meta-analyses on Positron Emission Tomography/Computed Tomography (PET/CT) or Positron Emission Tomography/Magnetic Resonance (PET/MR) in PCa were selected. We have summarized the diagnostic performance of PET imaging in PCa, taking into account 39 meta-analyses published in the literature. Evidence-based data showed the good diagnostic performance of PET/CT with several radiopharmaceuticals, including prostate-specific membrane antigen (PSMA)-targeted agents, radiolabeled choline, fluciclovine, and fluoride in restaging and staging settings. Less evidence-based data were available for PET/MR with different radiotracers. More prospective multicentric studies and cost-effectiveness analyses are warranted.

Application of11C-acetate positron-emission tomography (PET) imaging in prostate cancer: systematic review and meta-analysis of the literature

2013 ◽  
Vol 112 (8) ◽  
pp. 1062-1072 ◽  
Author(s):  
Beheshti Mohsen ◽  
Treglia Giorgio ◽  
Zakavi Seyed Rasoul ◽  
Langsteger Werner ◽  
Ghodsi Rad Mohammad Ali ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Systematic Review ◽  
Positron Emission Tomography ◽  
Pet Imaging ◽  
Meta Analysis ◽  
Emission Tomography ◽  
Positron Emission
Sign in / Sign up

Export Citation Format

Share Document